Find trials
Consejos para buscar

A Study to Evaluate the Use of Platelet-rich Plasma to Treat Erectile Dysfunction

Overview

Información sobre este estudio

The purpose of this study is to develop and implement an innovative treatment for erectile dysfunction (ED).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • The patient must have given his informed and signed written consent.
  • The patient is a male.
  • Between 45 and 65 years of age.
  • The patient has ED for longer than 1 year but less than 5 years.
  • The subject has a stable partner for at least 3 months.
  • The patient is PDE5i responsive, meaning he is able to achieve and maintain an erection under the effect of the maximal dosage of PDE5i.
  • IIEF-EF, EHS, SEP 2+3, and GAQ Domain score of 17-20.
  • Mild to moderate vascular erectile dysfunction: PSV > 25 cm/sec.

Exclusion Criteria:

  • The patient is participating in another study that may interfere with the results or conclusions of this study.
  • History of radical prostatectomy or pelvic cancer surgery.
  • Prior history of pelvic malignancies.
  • Prior pelvic radiation therapy.
  • Neurological disease which effects erectile function (spinal cord injury, iatrogenic injury to the pelvic or cavernous nerves).
  • Psychiatric disease which effects erectile function.
  • The patient is taking blood thinners.
  • History of Diabetes Mellitus.
  • History of Coronary Artery Disease.
  • Evidence Based Criteria: Doppler Clinical Exam ( PSV < 25 cm/sec defined criteria for severe erectile dysfunction not likely to respond to approved medical therapies).
  • Biochemical evidence of Hypogonadism (total Testosterone < 300 ng/dL).

Eligibility last updated 11/30/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Gregory Broderick, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20509175

Mayo Clinic Footer